Financial toxicity, a treatment-related financial burden, is a major concern among patients with bladder cancer and is common among younger patients, a recent study has shown. Those who endorse financial toxicity face delays in care and have poorer health-related quality of life (HRQOL), suggesting the critical role of treatment costs in medical decision-making.
A recent phase III study has found that office-based blue light flexible cystoscopy significantly improves the detection of patients with recurrent bladder cancer and is safe for surveillance. Blue light cystoscopy in the operating room also improves the detection of carcinoma in situ and exposes lesions that are missed with white light cystoscopy.
False over- and understaging seems to be common with the use of endoscopic ultrasound (EUS) to stage Barrett’s oesophagus (BE) patients with early neoplasia and dysplasia, a recent meta-analysis has shown.
Higher levels of physical activity appear to reduce the risk of developing colon cancer, independent of colonic subsite, according to a study. Conversely, sedentary behaviour is associated with an increased risk.
Urothelial carcinoma patients presenting with concomitant carcinoma in situ (CIS) appear to have a worse outcome than those presenting with pure/primary CIS, a recent study has found. This suggests that the two entities must be differentiated in the treatment decision process.
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.